Oncotarget

Research Papers:

Identifying drug-pathway association pairs based on L1L2,1-integrative penalized matrix decomposition

Dong-Qin Wang, Ying-Lian Gao, Jin-Xing Liu _, Chun-Hou Zheng and Xiang-Zhen Kong

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:48075-48085. https://doi.org/10.18632/oncotarget.18254

Metrics: PDF 1099 views  |   HTML 1883 views  |   ?  


Abstract

Dong-Qin Wang1, Ying-Lian Gao2, Jin-Xing Liu1, Chun-Hou Zheng1 and Xiang-Zhen Kong1

1School of Information Science and Engineering, Qufu Normal University, Rizhao, China

2Library of Qufu Normal University, Qufu Normal University, Rizhao, China

Correspondence to:

Jin-Xing Liu, email: [email protected]

Chun-Hou Zheng, email: [email protected]

Keywords: L2,1-norm, L1-norm, integrative penalized matrix decomposition, paired drug-pathway associations, drug discovery

Received: January 23, 2017     Accepted: May 01, 2017     Published: May 29, 2017

ABSTRACT

The traditional methods of drug discovery follow the “one drug-one target” approach, which ignores the cellular and physiological environment of the action mechanism of drugs. However, pathway-based drug discovery methods can overcome this limitation. This kind of method, such as the Integrative Penalized Matrix Decomposition (iPaD) method, identifies the drug-pathway associations by taking the lasso-type penalty on the regularization term. Moreover, instead of imposing the L1-norm regularization, the L2,1-Integrative Penalized Matrix Decomposition (L2,1-iPaD) method imposes the L2,1-norm penalty on the regularization term. In this paper, based on the iPaD and L2,1-iPaD methods, we propose a novel method named L1L2,1-iPaD (L1L2,1-Integrative Penalized Matrix Decomposition), which takes the sum of the L1-norm and L2,1-norm penalties on the regularization term. Besides, we perform permutation test to assess the significance of the identified drug-pathway association pairs and compute the P-values. Compared with the existing methods, our method can identify more drug-pathway association pairs which have been validated in the CancerResource database. In order to identify drug-pathway associations which are not validated in the CancerResource database, we retrieve published papers to prove these associations. The results on two real datasets prove that our method can achieve better enrichment for identified association pairs than the iPaD and L2,1-iPaD methods.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18254